Floatz logo

Evomela

Biphenotypic/Undifferentiated Leukemia

Masonic Cancer Center, University of MinnesotaPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

45 Active assets in the Biphenotypic/Undifferentiated Leukemia cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
SWOG Cancer Research Network
Phase 2BB
L-Ofloxacin
Children's Oncology Group
Phase 3BB
Cytosin-Arabinosid
SWOG Cancer Research Network
Phase 2B
METHOTREXATE
SWOG Cancer Research Network
Phase 2B
VINCRISTINE SULFATE
Children's Oncology Group
Phase 2B

View all 50 →

Same molecule, other indications

Evomela is also rated in:

diffuse large B-cell lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmDormant
BBB
Indicative ·
76 / 100
View asset →
myeloproliferative neoplasmDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →